{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:05:00Z","timestamp":1767999900350,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.clml.2018.06.025","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T22:53:34Z","timestamp":1530140014000},"page":"e463-e468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron","family":"Gerds","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derrick","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Martynova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Pannell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-2603","authenticated-orcid":false,"given":"Sudipto","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9227-5789","authenticated-orcid":false,"given":"Caitlin","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkael","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey","family":"O'Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.06.025_bib1","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.025_bib2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2018.06.025_bib3","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib4","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib5","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2012-05-399048","article-title":"Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors","volume":"120","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2018.06.025_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.025_bib8","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.025_bib9","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.025_bib11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3324\/haematol.2014.115840","article-title":"Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I","volume":"100","author":"Verstovsek","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.025_bib12","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2018.06.025_bib14","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nature11303","article-title":"Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy","volume":"489","author":"Koppikar","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clml.2018.06.025_bib16","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc3357","article-title":"Therapeutics: holding JAK back","volume":"12","author":"Burgess","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2018.06.025_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajh.23637","article-title":"Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis","volume":"89","author":"Gisslinger","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2018.06.025_bib18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s00277-017-2938-5","article-title":"Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis","volume":"96","author":"Cerchione","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2018.06.025_bib19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.06.025_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2018.06.025_bib23","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Newberry","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.06.025_bib24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.3324\/haematol.2013.092155","article-title":"Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I","volume":"98","author":"Verstovsek","year":"2013","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:54Z","timestamp":1761870714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018302593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":24,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S2152265018302593"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.025","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}